epiR (version 2.0.76)

epi.sssupb: Sample size for a parallel superiority trial, binary outcome

Description

Sample size for a parallel superiority trial, binary outcome.

Usage

epi.sssupb(treat, control, delta, n, power, r = 1, nfractional = FALSE, alpha)

Value

A list containing the following:

n.total

the total number of study subjects required.

n.treat

the required number of study subject in the treatment group.

n.control

the required number of study subject in the control group.

delta

the equivalence limit, as entered by the user.

power

the specified or calculated study power.

Arguments

treat

the expected proportion of successes in the treatment group.

control

the expected proportion of successes in the control group.

delta

the equivalence limit, expressed as the absolute change in the outcome of interest that represents a clinically meaningful difference. For a superiority trial the value entered for delta must be greater than or equal to zero.

n

scalar, the total number of study subjects in the trial.

power

scalar, the required study power.

r

scalar, the number in the treatment group divided by the number in the control group.

nfractional

logical, return fractional sample size.

alpha

scalar, defining the desired alpha level.

References

Chow S, Shao J, Wang H (2008). Sample Size Calculations in Clinical Research. Chapman & Hall/CRC Biostatistics Series, page 90.

Julious SA (2004). Sample sizes for clinical trials with normal data. Statistics in Medicine 23: 1921 - 1986.

Pocock SJ (1983). Clinical Trials: A Practical Approach. Wiley, New York.

Wang B, Wang H, Tu X, Feng C (2017). Comparisons of superiority, non-inferiority, and equivalence trials. Shanghai Archives of Psychiatry 29, 385 - 388. DOI: 10.11919/j.issn.1002-0829.217163.

Examples

## EXAMPLE 1 (from Chow S, Shao J, Wang H 2008, p. 91):
## Suppose that a pharmaceutical company is interested in conducting a
## clinical trial to compare the efficacy of two antimicrobial agents 
## when administered orally once daily in the treatment of patients 
## with skin infections. In what follows, we consider the situation 
## where the intended trial is for testing superiority of the 
## test drug over the active control drug. For this purpose, the following 
## assumptions are made. First, sample size calculation will be performed 
## for achieving 80% power at the 5% level of significance.

## Assume the true mean cure rates of the treatment agents and the active 
## control are 85% and 65%, respectively. Assume the superiority
## margin is 5%.

epi.sssupb(treat = 0.85, control = 0.65, delta = 0.05, n = NA, 
   power = 0.80, r = 1, nfractional = FALSE, alpha = 0.05)

## A total of 196 subjects need to be enrolled in the trial, 98 in the 
## treatment group and 98 in the control group.